media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

MEDICA

Organiser: MEDICA Time：November 17 – November 20, 2025 address：Stockumer Kirchstraße 61, D-40474 Düsseldorf, Germany Exhibition hall：Dusseldorf Exhibition Center Product range: Medical Equipment: Medical electronic instruments, clinical laboratory analytical instruments, dental equipment and materials, hemodialysis equipment, respiratory equipment, hospital ward, operating room, and emergency room equipment, hospital office equipment, etc. Imaging and Diagnostics: Ultrasound instruments, X-ray equipment, medical optical instruments Disposable Consumables: Disposable medical supplies, dressings and hygienic materials, various surgical instruments, etc. Medical Devices: Healthcare equipment, home healthcare products, physiotherapy, orthopedic technology, etc. Medical Peripherals: Information and communication technology, medical services and publications, IT systems and IT solutions, etc. Laboratory Equipment Physical Therapy/Orthopedic Technology About MEDICA： The MEDICA Exhibition in Düsseldorf, Germany, is the world’s largest and most authoritative exhibition for hospitals and medical equipment. It holds an unparalleled position as the premier medical trade show globally due to its scale and influence. Held annually in Düsseldorf, Germany, MEDICA ...
- Source: drugdu
- 25
- September 23, 2025
Eli Lilly invests $5 billion in U.S. plant to expand production of targeted cancer drugs and other therapies

On Tuesday, US Eastern Time, US pharmaceutical giant Eli LillyEli Lilly announced a $5 billion investment in a manufacturing facility in Goochland County, Virginia, to increase production of APIs and finished products for advanced therapies such as targeted cancer drugs. During U.S. trading, Eli Lilly’s stock price rose by over 2.5%. Eli Lilly stated that the new plant will be used to produce active ingredients for cancer and autoimmune disease drugs, as well as other advanced therapies. Eli Lilly emphasized that the plant will significantly enhance the local production capacity of antibody-drug conjugates (ADCs). ADCs are an emerging class of targeted therapies, often referred to as “biological missiles” in the industry. They combine monoclonal antibodies with toxic “payloads” to kill cancer cells. Currently, several pharmaceutical companies are developing or have already launched these drugs and are exploring their use in autoimmune diseases and other indications. “This is new capacity to ...
- Source: drugdu
- 36
- September 22, 2025
The investment logic of multinational pharmaceutical companies has changed

Recently, multiple sources have indicated that Bristol-Myers Squibb(BMS) will sell 60% of its stake in Shanghai Bristol-Myers Squibb Co., Ltd., and the buyer may be an affiliate of Hillhouse Capital Group. According to an email circulating online, BMS has signed an agreement to sell its 60% stake in Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd. and several related products manufactured and sold exclusively in mainland China to an affiliate of Hillhouse Capital. These products include Baraclude, Bufferin, Theragran, Monopril, and Velosef (Velosef). The transaction is expected to close in early 2026, and the specific amount was not disclosed. BMS stated that this divestiture will help it focus resources on core areas and optimize its business layout. BMS divests major assets According to data, in 1982, Shanghai Bristol-Myers Squibb was established by the American company Bristol-Myers Squibb and Shanghai Pharmaceuticals, the predecessor of Shanghai Pharmaceuticals Group.It was established as a joint venture ...
- Source: drugdu
- 35
- September 22, 2025
Changchun High-Tech invested nearly 1.5 billion yuan to introduce three new drugs

On September 17, Changchun High-Tech announced that its holding subsidiary Jinsai Pharmaceuticals had reached an allergen-specific immunotherapy (AIT) product cooperation with Denmark’s ALK-Abelló A/S (ALK). The company will jointly develop and commercialize ALK’s house dust mite (HDM) allergen-specific immunotherapy products in China, and obtain exclusive agency rights for three products independently developed by ALK in mainland China. According to the agreement, Jinsai Pharmaceutical will pay an initial payment of €32.7 million and a €40 million registration milestone payment for the dust mite allergen sublingual tablet (ACARIZAX) in China. Jinsai Pharmaceutical will also cover the majority of future Phase III bridging clinical study and registration costs for adult and adolescent indications, while both parties will each cover 50% of the clinical study and registration costs for pediatric indications. Furthermore, depending on the sales performance of these products in the Chinese market, Jinsai Pharmaceutical may make subsequent sales milestone payments of €105 ...
- Source: drugdu
- 28
- September 22, 2025
WALVAX’s clinical application for freeze-dried herpes zoster virus mRNA vaccine has been accepted

On September 19, WALVAX(300142) announced that its subsidiaries, Beijing Watson Innovation Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi WALVAXtechnology Co., Ltd., jointly developed with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd., have submitted their clinical trial application to the National Medical Products Administration and received a “Notice of Acceptance.” The vaccine’s primary function is to stimulate immunity against the herpes zoster virus and is intended for the prevention of shingles. The announcement mentioned that the acceptance numbers of the vaccine application are CXSL2500804 and CXSL2500805, and the registration classification is a preventive biological product.1.2. According to relevant regulations, after an application is accepted, it must undergo a technical review by the Center for Drug Evaluation of the National Medical Products Administration and obtain approval before clinical trials can begin. By mid-2025, WALVAX achieved revenue of 1.154 billion yuan and net profit attributable to shareholders of ...
- Source: drugdu
- 35
- September 22, 2025
New neuro-sensing technique captures brainwaves from within veins

Researchers at The University of Osaka have developed a groundbreaking, minimally invasive method for recording brain activity through blood vessels. This technique could potentially transform the diagnosis and treatment of neurological conditions like epilepsy and paving the way for advanced brain-computer interfaces. It eliminates the need for invasive open-brain surgery, offering a safer and more accessible way to monitor and stimulate brain function. Current methods for directly measuring brain activity require invasive procedures, either removing part of the skull to place electrodes on the brain surface or inserting electrodes directly into brain tissue. While non-invasive methods like EEG exist, they lack the precision needed for detailed analysis. This new method bridges the gap, offering high-fidelity recordings without the risks associated with traditional invasive approaches. The research team, led by Professor Takufumi Yanagisawa used a catheter to insert ultra-thin wire electrodes into the cortical and deep veins of pig brains. They ...
- Source: drugdu
- 37
- September 22, 2025
Why Mosquitos Might Be Attracted To You

By Deanna Neff HealthDay ReporterSATURDAY, Sept. 20, 2025 (HealthDay News) — Researchers in the Netherlands turned a major music festival into an unexpected laboratory to investigate a question that has long puzzled scientists and bug-bitten individuals alike: What makes some people more irresistible to mosquitoes than others? For three consecutive days at the Lowlands festival in Biddinghuizen, Netherlands, scientists set up a unique pop-up research site inside a series of shipping container laboratories. Instead of waiting for their favorite band, hundreds of festivalgoers lined up to volunteer for the “Mosquito Magnet Trial,” a study designed to measure their personal attractiveness to the insects. Inside the make-shift lab from 9 a.m. to 10 p.m. each day, groups of participants rested their arms against transparent acrylic boxes that had caged mosquitoes. As the insects responded to the human scent, a camera and computer system recorded mosquito movements and calculated a unique attraction ...
- Source: drugdu
- 37
- September 22, 2025
【EXPERT Q&A】What are the difficulties in applying for CE under the EU in vitro Diagnostic (IVDR) regulation?

Drugdu.com expert’s response: I. Complex Classification Rules The IVDR expands the risk classification of in vitro diagnostic products from four categories (e.g., List A/B under IVDD) to four classes (A-D), with criteria spanning sample types (e.g., saliva, skin tissue) and disease risks (e.g., infectivity, mortality). For example: Class D devices (e.g., HIV or COVID-19 test kits) require submission of a Clinical Performance Study Plan (CPSR) and independent testing by EU Reference Laboratories (EURLs). Class C devices (e.g., tumor biomarker tests) necessitate enhanced performance evaluations and clinical evidence reviews. Challenge: Insufficient understanding of classification rules may lead to errors in technical documentation or clinical strategies, requiring costly compliance adjustments. Elevated Clinical Evidence Requirements The IVDR mandates more comprehensive clinical evidence, including: Scientific Validity: Verification of the product’s correlation with specific diseases, conditions, or parameters. Analytical Performance: Demonstration of sensitivity, specificity, and other metrics through laboratory testing. Clinical Performance: Validation of intended use via real-world data. Case ...
- Source: drugdu
- 33
- September 22, 2025
【EXPERT Q&A】What are the functions of the FDA’s consensus standards for medical devices and how can they be queried?

Drugdu.com expert’s response: I. Functions: Regulating Safety and Effectiveness of Medical Devices and Accelerating Market Access Ensuring Safety and Effectiveness The consensus standards recognized by the FDA provide clear specifications for the design, testing, and clinical evaluation of medical devices through scientifically validated test methods, acceptance criteria, and risk management processes. For example, biocompatibility standards (such as the ISO 10993 series) stipulate safety testing requirements for materials in contact with human tissues, ensuring that products do not trigger toxicity or allergic reactions. Streamlining Regulatory Processes Manufacturers who can demonstrate that their products comply with FDA-recognized consensus standards can reduce redundant testing and document submissions, thereby shortening the pre-market review time. For instance, in a 510(k) application, products that meet consensus standards can expedite approval through “substantial equivalence” demonstration. Enhancing Industry Transparency Consensus standards offer a unified framework for performance indicators and labeling instructions, facilitating the understanding of product characteristics by ...
- Source: drugdu
- 56
- September 19, 2025
Zhengda Tianqing targets 9.2 billion yuan drug

On September 15, the injectable degarelix acetate (Qinglishu) independently developed by Zhengda Tianqing obtained the drug registration certificate issued by the National Medical Products Administration (NMPA) for use in prostate cancer patients who require androgen deprivation therapy. As the original drug in this category, degarelix acetate (fermonger)’s global sales exceeded US$1.3 billion (approximately RMB 9.2 billion) in 2024. Is Zhengda Tianqing, the “pioneer in anti-tumor innovation”, brewing a blockbuster drug? 01 Approved for listing in three locations The original developer of Degarelix Acetate for Injection is Ferring Pharmaceuticals. As a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist, the clinical value of Degarelix Acetate in the treatment of prostate cancer has long been recognized worldwide. This drug can effectively reduce the release of gonadotropin and testosterone by reversibly binding to the GnRH receptors in the pituitary gland, thereby inhibiting the growth and spread of prostate cancer cells from the root. Especially in ...
- Source: drugdu
- 70
- September 18, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.